The shadow of generic rivalry has long loomed over copyright’s famous drug, PDE5 Inhibitor, raising questions about the outlook of related pharmaceutical portfolios. While early times saw impressive returns, the patent lapse has allowed the path for discounted substitutes, likely lowering profita